皮肤恶性黑色素瘤患者的血清总25-羟基维生素D水平：一项针对低风险南欧人群的病例对照研究

Serum Total 25-Hydroxyvitamin D Levels in Patients With Cutaneous Malignant Melanoma: A Case-Control Study in a Low-Risk Southern European Population.

作者信息

Befon Angeliki, Katoulis Alexander C, Georgala Sofia, Katsampas Andreas, Chardalia Vasiliki, Melpidou Aggeliki, Tzanetakou Vasiliki, Chasapi Vasiliki, Polydorou Dorothea, Desinioti Clio, Plaka Micaela, Rigopoulos Dimitris, Stratigos Alexandros J

机构信息

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Second Department of Dermatology and Venereology, Attikon General University Hospital, National and Kapodistrian University of Athens, Greece.

出版信息

Dermatol Pract Concept. 2019 Dec 31;10(1):e2020010. doi: 10.5826/dpc.1001a10. eCollection 2020.

DOI:10.5826/dpc.1001a10

PMID:31921497

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6936640/

Abstract

BACKGROUND

Recent data have shown an inverse association between serum 25-hydroxyvitamin D concentration and incidence of several cancers, including cutaneous malignant melanoma (CMM). In addition, lower serum 25-hydroxyvitamin D levels have been associated with thicker or higher stage melanomas and worse survival in observational studies.

MATERIALS AND METHODS

Ninety-nine patients diagnosed with primary CMM and 97 matched healthy controls entered the study. Demographic characteristics, risk factors for CMM, and clinical and histological characteristics were recorded for patients with primary CMM. Total serum 25-hydroxyvitamin D levels of melanoma patients measured by fully automated chemiluminescent vitamin D total immunoassay (Elecsys vitamin D total, Roche) at the time of diagnosis were compared with those of healthy controls. In addition, we tested the association of serum total 25-hydroxyvitamin D levels at melanoma diagnosis with known risk and prognostic factors for CMM.

RESULTS

Of the melanoma patients, 49 (49.49%) had deficient serum total 25-hydroxyvitamin D levels (<20 ng/mL), 23 (23.23%) had insufficient levels (21-29 ng/mL), and 27 (27.27%) had adequate levels (>30 ng/mL). The median serum total 25-hydroxyvitamin D levels were significantly lower in melanoma patients (20.62 ng/mL) compared with healthy controls (24.71 ng/mL), but statistical significance was not reached (chi-square test, P = 0.051) No statistically significant association was found between serum total 25-hydroxyvitamin D levels and demographic characteristics; risk factors for CMM; prognostic factors, such as Breslow thickness and ulceration; as well as clinical characteristics, such as melanoma stage, clinical type, and location.

CONCLUSIONS

Lower serum 25-hydroxyvitamin D levels were found in our Greek cohort of melanoma patients compared with healthy controls, without reaching, however, statistical significance; these levels were not statistically associated with established risk and prognostic factors for CMM.

摘要

背景

近期数据显示，血清25-羟基维生素D浓度与包括皮肤恶性黑色素瘤（CMM）在内的多种癌症的发病率呈负相关。此外，在观察性研究中，较低的血清25-羟基维生素D水平与黑色素瘤厚度增加、分期较高以及较差的生存率相关。

材料与方法

99例诊断为原发性CMM的患者和97例匹配的健康对照者进入本研究。记录原发性CMM患者的人口统计学特征、CMM的危险因素以及临床和组织学特征。采用全自动化学发光维生素D总免疫测定法（Elecsys维生素D总测定法，罗氏公司）在诊断时测量黑色素瘤患者的血清总25-羟基维生素D水平，并与健康对照者的水平进行比较。此外，我们测试了黑色素瘤诊断时血清总25-羟基维生素D水平与已知的CMM风险和预后因素之间的关联。

结果

在黑色素瘤患者中，49例（49.49%）血清总25-羟基维生素D水平不足（<20 ng/mL），23例（23.23%）水平不充足（21 - 29 ng/mL），27例（27.27%）水平充足（>30 ng/mL）。黑色素瘤患者的血清总25-羟基维生素D水平中位数（20.62 ng/mL）显著低于健康对照者（24.71 ng/mL），但未达到统计学显著性（卡方检验，P = 0.051）。血清总25-羟基维生素D水平与人口统计学特征、CMM危险因素、预后因素（如Breslow厚度和溃疡）以及临床特征（如黑色素瘤分期、临床类型和部位）之间未发现统计学显著关联。